NurOwn Now Being Produced at 2nd U.S. Manufacturing Site, Brainstorm Announces

BrainStorm Cell Therapeutics has partnered with the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute for the manufacturing of NurOwn, a therapy candidate for amyotrophic lateral sclerosis (ALS), for BrainStorm’s ongoing Phase 3 trial. This is the second U.S. production site…

Israel’s BrainStorm Initiates Technology Transfer to City of Hope for NurOwn ALS Phase 3 Study

BrainStorm Cell Therapeutics has begun training the cell manufacturing team at City of Hope’s Center for Biomedicine and Genetics to produce NurOwn adult stem cells for a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Los Angeles-based City of Hope will be the clinical…